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Abstract
Background We have treated three patients with carboxy-
anhydrase-IX (CAIX) positive metastatic renal cell cancer
(RCC) by adoptive transfer of autologous T-cells that had
been gene-transduced to express a single-chain antibody-
G250 chimeric receptor [scFv(G250)], and encountered
liver toxicity necessitating adaptation of the treatment proto-
col. Here, we investigate whether or not the in vivo activity
of the infused scFv(G250)+ T cells is reXected by changes of
selected immune parameters measured in peripheral blood.
Methods ScFv(G250)-chimeric receptor-mediated func-
tions of peripheral blood mononuclear cells (PBMC)
obtained from three patients during and after treatment
were compared to the same functions of scFv(G250)+ T
lymphocytes prior to infusion, and were correlated with
plasma cytokine levels.
Results Prior to infusion, scFv(G250)+ T lymphocytes
showed in vitro high levels of scFv(G250)-chimeric receptor-
mediated functions such as killing of CAIX+ RCC cell lines
and cytokine production upon exposure to these cells. High
levels of IFN- were produced, whilst production of TNF-,
interleukin-4 (IL-4), IL-5 and IL-10 was variable and to lower
levels, and that of IL-2 virtually absent. PBMC taken from
patients during therapy showed lower levels of in vitro
scFv(G250)-receptor-mediated functions as compared to
pre-infusion, whilst IFN- was the only detectable cytokine
upon in vitro PBMC exposure to CAIX. During treatment,
plasma levels of IFN- increased only in the patient with the
most prominent liver toxicity. IL-5 plasma levels increased
transiently during treatment in all patients, which may have
been triggered by the co-administration of IL-2.
Conclusion ScFv(G250)-receptor-mediated functions of
the scFv(G250)+ T lymphocytes are, by and large, pre-
served in vivo upon administration, and may be reXected by
Xuctuations in plasma IFN- levels.
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Introduction
Adoptive transfer of autologous T lymphocytes that have
been gene-transduced to express antigen-speciWc receptors
is a potentially attractive therapy to provide tumor-speciWc
immunity to cancer patients [1–4]. We have studied safety
and proof of this concept in patients with metastatic renal
cell cancer (RCC) [5–7]. To this end we have constructed a
single-chain antibody-type (scFv) receptor based on murine
monoclonal antibody (mAb) G250 [8]. This mAb recog-
nizes an epitope on carboxy-anhydrase-IX (CAIX) that is
over-expressed by RCC cells [9]. Following retroviral
introduction of the scFv(G250) transgene into primary
human T-cells, the scFv(G250) receptor is expressed on the
surface of these cells, which enables them to recognize
CAIX and subsequently to exert antigen-speciWc eVector
functions in terms of cytokine production and killing of
CAIX+ RCC cell lines [5, 10].
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1876 Cancer Immunol Immunother (2007) 56:1875–1883In a phase I study we have treated three patients with
metastatic RCC with autologous scFv(G250)+ T cells and
subcutaneous (s.c.) injections of low dose interleukin-2 (IL-
2). Unexpectedly, liver toxicity was encountered, after
which the study was temporarily put on hold [7]. Examina-
tion of liver tissue from patient 1 revealed a discrete cho-
langitis with T-cell inWltration around the bile ducts and
CAIX expression on the bile duct epithelium. The observed
liver toxicity, reXected by liver enzyme disturbances, was
most likely to be due to speciWc interactions of the
scFv(G250)+ infused T cells with CAIX+ epithelial cells
lining the bile ducts.
We hypothesized that the liver toxicity reXects a speciWc
immune reaction by the infused scFv(G250)+ T cells and
expected that this reaction would be reXected in changes of
immune parameters measured in peripheral blood during
and after therapy. Therefore, we compared functions of the
scFv(G250)+ T cells prior to and post infusion—the latter
using peripheral blood mononuclear cells (PBMC) taken
from the patients after infusion. We tested scFv(G250)-chi-
meric receptor-mediated functions, such as killing of
CAIX+ RCC cell lines and cytokine production upon expo-
sure to CAIX, and determined plasma cytokine levels.
Materials and methods
Treatment schedule
The inclusion and exclusion criteria for patients participat-
ing in this study have been reported previously [7]. The
main eligibility criteria were that patients had disseminated
clear cell RCC not amenable for surgery, and that the pri-
mary tumor had been removed by nephrectomy and
expressed CAIX.
Autologous T lymphocytes were transduced with the
scFv(G250)-chimeric receptor using retroviral transduction
[11, 12]. The treatment schedule consisted of i.v. infusions of
autologous scFv(G250)-transduced T-cells at escalating doses
of 2 £ 107 cells at day 1; 2 £ 108 cells at day 2; 2 £ 109 cells
at days 3–5 (treatment cycle 1) and 2 £ 109 cells at days 17–
19 (treatment cycle 2), combined with s.c. human recombi-
nant interleukin-2 (rIL-2, Chiron, Amsterdam), 5 £ 105 IU/
m2 twice daily administered at days 1–10 and days 17–26.
The treatment protocol had been approved by the governmen-
tal and institutional medical ethical review boards. Written
informed consent was obtained from all patients.
Collection of peripheral blood mononuclear cells 
and plasma
Peripheral venous blood samples were drawn prior to, dur-
ing and after treatment. During therapy blood was obtained
prior to the Wrst IL-2 injection unless indicated otherwise.
PBMC were isolated from sodium heparin-anti-coagulated
blood by Ficoll density gradient centrifugation and were
cryopreserved in liquid nitrogen. Plasma was harvested
from EDTA-anti-coagulated blood by centrifugation for
10 min at 1,000£g and stored at ¡70°C.
Flow cytometric analysis of transduced T-cell infusions 
and patient blood samples
The expression of the scFv(G250) receptor on transduced
T-cell cultures was studied by indirect immunoXuorescence
using G250 anti-idiotype mAb NuH82 [10, 13]. The abso-
lute numbers of scFv(G250)+ T-cells in the blood of
patients prior to and following infusions of transduced
T-cells were assessed as described [14].
Assessment of scFv(G250)-chimeric receptor-mediated 
functions in transduced T-cell infusions and patient blood 
samples
Cultures of scFv(G250)-gene modiWed T cells to be used
for adoptive immunogene therapy, as well as patient PBMC
obtained prior to and after infusion of gene-modiWed T
cells, were monitored for scFv(G250)-chimeric receptor-
mediated functions, i.e. speciWc cytotoxic activity and cyto-
kine production, using the CAIX+ RCC cell line SKRC17-
MW1 (clone 4) [10, 11]. A scFv(G250)-chimeric receptor-
expressing T-cell clone (Clone 46) was used as positive
control in these assays.
Cytotoxic activity was measured in a standard 4 h 51Cr-
release assay, at 2,500 target cells per well and eVector cell/
target cell ratios (E/T) of 80, 40, 20, 10, 5, 2.5, 1.25 and
0.63:1. The activated kill (AK)-activity of the cultured T
cells and patient PBMC was blocked by adding a 30-fold
excess of non-51Cr-labelled (“cold”) AK-sensitive target
cells (i.e. K562) to the test. The speciWcity of the
scFv(G250)-mediated eVector functions was veriWed by
blocking CAIX on the target cells by adding G250 mAb (at
a saturating Wnal concentration of 25 g/ml) to the target
cells 15 min before addition of the eVector cells [10, 11].
The speciWc cytolytic activity, i.e. speciWc 51Cr-release
(see Fig. 1, upper panels), was expressed as LU20 per 106 T
lymphocytes, in which one lytic unit (LU20) is deWned as
the number of eVector cells required to lyse 20% of 2,500
target cells in a standard 4 h 51Cr-release test [15]. The net
CAIX-speciWc cytolysis is deWned as the level of cytolysis
on CAIX+ RCC cells in the presence of cold K562 targets
minus the level of cytolysis on the CAIX+ RCC cells in the
presence of cold K562 targets and blocking G250 mAb.
For comparison of level of CAIX-speciWc activities
between the T cell infusions of the individual patients the
speciWc cytolytic activity and cytokine production were123
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rect for assay variation these activities were related to the
positive test control.
Assessment of cytokine levels
The concentrations of IFN-, TNF-, IL-2, IL-4, IL-5 and
IL-10 in plasma samples and culture supernatants (see
above) were determined by cytokine bead arrays (BD Bio-
sciences, San Jose, CA, USA), according to suppliers’
speciWcations, and expressed in pg/ml. The detection limits
of the assay were 2.6 pg/ml for IL-2 and IL-4, 2.5 pg/ml for
IL-5, 2.8 pg/ml for IL-10 and TNF- and 7.1 pg/ml for
IFN-. Cytokine production by scFv(G250)-gene modiWed
T cells was expressed as ng cytokine produced by 106 T
cells per 24 h.
Assessment of transgene copy number by quantitative 
real-time PCR
Genomic DNA was isolated from aliquots of the transduced
T-cell infusions and from blood taken prior to, during and
after therapy using the QIAamp® DNA mini kit (Qiagen,
Hilden, Germany). The quantitative real-time PCR was per-
formed as described [14], and data is presented as number
of scFv(G250) DNA copies per l of blood.
Results
Liver toxicity following scFv(G250)+ T cell infusions
The three patients initially tolerated the infusions of the
gene-modiWed T-cells well. However, following four to
Wve infusions liver enzyme disturbances developed, reach-
ing CTC grade 4 in patient 1, grade 2 in patient 2 and
grade 3 in patient 3 (Fig. 2). The severe liver toxicity in
patient 1 also included elevated levels of bilirubin. The
severity of the liver toxicity was less during the second
treatment cycle than during the Wrst in patient 2. These
toxicities required cessation of treatment in patients 1 and
3, corticosteroid treatment for patient 1 and reduction of
the maximal T-cell dose to 2 £ 108 total T-cells per infu-
sion in patients 2 and 3.
Fig. 1 Carboxy-anhydrase-IX-speciWc cytolysis by scFv(G250)-gene
modiWed T cell cultures used for adoptive immunogene therapy. The
upper panels show representative experiments from each individual
patient. The results are expressed as % 51Cr-release (4 h assay) at eight
eVector-to-target (E:T) cell ratios. Target cell were derived from the
CAIX+ RCC cell line SKRC17-MW1 clone 4, alone (dotted line, for
patient #2 and #3 only), in presence of a 30-fold excess of ‘cold’ K562
cells (closed circles), and in presence of a 30-fold excess of “cold”
K562 cells and 25 g/ml (Wnal concentration) G250mAb (open cir-
cles). The net CAIX-speciWc cytolysis was deWned as the level of
cytolysis on CAIX+ RCC cells (in the presence of cold K562 targets)
minus the level of cytolysis on CAIX+ RCC cells (in the presence of
cold K562 targets and blocking G250 mAb). From these data, CAIX-
speciWc lytic units (LU20) were calculated according to Pross et al.
[15]. The lower panel shows the LU20-values per 106 scFv(G250)+ T
cells for the individual T-cell infusions and the mean value (horizontal
line) per patient. The open circles in the lower panel indicate the posi-
tive test control results. DiVerences between patients were assessed by
Student’s t-test (two-sided); P values · 0.05 are indicated. Pat indi-
cates patient, C indicates treatment cycle123
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to infusion
The ex vivo generation of gene-modiWed T-cells was highly
successful [11, 12]. The proportions of scFv(G250)+ T
cells among the infused T cells were 53% for patient 1,
52% and 76 % for patient 2 (treatment cycle 1 and 2,
respectively), and 63% for patient 3. Due to the reduced
numbers of infused T-cells and early cessation of treatment
in patients 1 and 3, the total number of infused
scFv(G250)+ T-cells varied widely between patients,
namely 2.13 £ 109 cells for patient 1, 0.85 £ 109 cells for
patient 2 and 0.38 £ 109 cells for patient 3 [7].
In vitro screening of gene-modiWed T-cells prior to infu-
sion demonstrated high levels of scFv(G250)-mediated
cytolysis of a CAIX+ RCC cell line (Fig. 1, upper panels).
The CAIX-speciWc cytolytic activity of the scFv(G250)+
T-cells of patient 1 [i.e. median value 372 (range 186–433)
LU20 per 106 scFv(G250)+ T cells] was signiWcantly higher
than those of patient 2 [i.e. 93 (81–116) LU20 per 106 cells]
and patient 3 [i.e. 88 (51–143) LU20 per 106 cells]. This pat-
tern was also observed when test results were corrected for
between-test variation (Fig. 1, lower panel). As a result, the
total scFv(G250)-mediated cytolytic capacities of the T-cell
infusions varied widely between patients, i.e. 792,204 LU20
for patient 1, 78,774 LU20 for patient 2 and 33,274 LU20 for
patient 3 [7].
Upon stimulation with CAIX+ RCC cells, the
scFv(G250)+ T-cells of individual patients showed a char-
acteristic cytokine production pattern (Table 1 and Fig. 3).
All T-cell cultures produced predominantly IFN- [ranging
between the patients from 36.9 to 55.9 ng IFN per 106
scFv(G250)+ T cells during 24 h], and to lower levels, IL-5
(ranging from 1.2 to 5.4 ng) and IL-4 (ranging from 0.3 to
2.9 ng). Only low levels of TNF-, IL-2 and IL-10 were
produced, although scFv(G250)+ T cells of patient 2 pro-
duced relatively high amounts of IL-10. These patterns
were also observed when test results were corrected for
between-test variation (not shown). In the absence of
CAIX-triggered stimulation, scFv(G250)+ T-cells showed
no detectable levels of spontaneous cytokine production
(data not shown).
As a consequence of the widely diVerent numbers of
infused scFv(G250)+ T cells between patients, the calculatedFig. 2 Kinetics of liver enzyme disturbances in the three patients be-
fore, during and following treatment with scFv(G250)+ T-cells. Treat-
ment intervals are indicated by horizontal bars; T-ly, daily infusions of
retargeted T lymphocytes; IL-2, 0.5 £ 106 IU rIL-2 s.c. every 12 h;
Corticosteroids, i.v. solumedrol (days 8–10) and oral prednisolon
(days 11–36). Treatment was stopped at day 5 after the 4th T-cell infu-
sion in patient 1 and patient 3. Patient 2 received eight T-cell infusions
as per protocol. For each patient, diVerent linear scales were used for
the y-axes in order to improve legibility of the panels
Table 1 Carboxy-anhydrase-IX-speciWc cytokine production capac-
ity of infused scFv(G250)+ T cells
Cytokine production capacity: ng per 106  scFv(G250)+  transduced T
cells per 24 h
Total number of infused scFv(G250)-transduced T cells: patient 1:
2.13 £ 109 , patient 2: 8.45 £ 108 , patient 3: 3.79 £ 108
nt not tested
Cytokine Patient 1 Patient 2 Patient 3
IFN- 42.0 55.9 36.9
TNF- 0.3 1.4 1.1
IL-2 nt 0.1 0.0
IL-4 2.9 1.3 0.3
IL-5 5.4 4.9 1.2
IL-10 0.1 1.5 0.0123
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infused gene-modiWed T-cells ranged between 89.5 g of
IFN- per 24 h for patient 1, 47.2 g for patient 2 and
14.0 g for patient 3.
Monitoring of peripheral blood samples
The treatment episodes were associated with transient
lymphopenia in all three patients, probably due to the co-
administered rIL-2. Circulating T-cell numbers decreased
immediately upon start of therapy to reach a nadir at
approximately 50% of baseline values on day 4, to normal-
ize again when treatment was stopped (not shown).
Circulating scFv(G250)+ T-cells and scFv(G250) DNA 
copies
ScFv(G250)+ T-cells became transiently detectable in the
circulation of all three patients from day 3 of therapy
onwards, and reached maximum levels between days 6
and 16 (Fig. 4, upper panels, and [14]). Their peak levels
during the Wrst therapeutic cycle were higher in patient 1
[5.3 scFv(G250)+ T cells/l] than in patient 2 (2.6 and 1.6
cells/l in treatment cycle 1 and 2, respectively) and
patient 3 (0.8 cells per l), which were proportional to
the numbers of scFv(G250)+ T-cells administered (see
above). In parallel scFv(G250)-encoding DNA became
transiently detectable in the circulation of all three
patients. Here, only limited numbers of samples of
patients 1 and 2 (Wrst treatment cycle) were available for
testing (Fig. 4, lower panels, and [14]). Again, the num-
ber of circulating scFv(G250) DNA copies was clearly
higher in patient 1 (i.e. 44 copies/l on day 10) than in
patients 2 (7.1 copies/l on day 17) and 3 (5.3 copies/l
on day 8).
ScFv(G250)-chimeric receptor-mediated functions 
in patient blood samples
Peripheral blood mononuclear cells obtained prior to and at
1–4 days following the last T-cell infusion were assayed for
in vitro scFv(G250)-mediated cytotoxicity and cytokine
(IFN-, TNF-, IL-2, IL-4, IL-5 and IL-10) production
upon co-culture with a CAIX+ RCC cell line. In all three
patients, CAIX-speciWc activities, i.e. cytolysis of CAIX+
RCC cells (Fig. 5, upper row of panels) and IFN- produc-
tion (2nd row of panels) were detected. Virtually no
scFv(G250)-receptor-mediated production of TNF-, IL-2,
IL-4, IL-5 and IL-10 was detectable (lower row of panels
and data not shown). The ex vivo CAIX-speciWc activities
of PBMC (i.e.cytolysis and IFN- production) obtained
during or immediately after administration of rIL-2 were
higher than those of PBMC obtained several days after ter-
mination of rIL-2 treatment in patients 1 and 3 (upper and
middle rows of panels). In contrast, patient 2 still showed
signiWcant levels of these activities at the start of cycle 2
(i.e. 1 week after cessation of IL-2 administration), which
were paralleled by high levels of circulating scFv(G250)+ T
cells and DNA copies (see before) and exceptionally high
IFN- plasma concentrations (see below),
Blood cytokine levels
Interleukin-2 became detectable during therapy; levels
were typically between 5 and 20 pg/ml in blood samples
drawn 12 h after s.c. injection of rIL-2 (Fig. 6, upper row).
Relatively high IL-2 plasma concentrations were observed
in blood samples taken shortly after rIL-2 injections
(marked with asterisks in Fig. 6). The Xuctuations in
plasma IFN- levels varied greatly between patients and as
a function of time (2nd row of panels): in patient 1, IFN-
Fig. 3 Carboxy-anhydrase-IX-
speciWc cytokine production 
(IFN-, TNF-, Il-2, IL4, IL-5 
and IL-10) by scFv(G250)-gene 
modiWed T-cells in the individ-
ual T cell infusions, expressed as 
the net amount [ng] of cytokine 
produced by 106 scFv(G250)+ T 
cells during 24 h of co-cultiva-
tion with the CAIX+ RCC cell 
line SKRC1-MW1 clone 4. For 
each cytokine, diVerent linear 
scales were used for the y-axes 
in order to improve legibility of 
the panels. See further legend to 
Fig. 1123
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decline after day 5 when treatment was stopped. Remark-
ably, patient 2 had constitutively high IFN- plasma con-
centrations prior to start of therapy (73 pg/ml), which
transiently declined to 31 pg/ml during the Wrst therapeutic
cycle. Prior to the second cycle, IFN- levels had increased
again to 115 pg/ml, but gradually declined during therapy
to levels »20 pg/ml on day 32. The IFN- levels of patient
3 remained relatively stable and Xuctuated between 7 and
14 pg/ml during the observation period. The IL-5 plasma
levels became detectable in all three patients during ther-
apy, to reach maximum levels following the last rIL-2
administration in treatment cycle 1, i.e. 97 pg/ml at day 5 in
patient 1, 50 pg/ml at day 10 in patient 2, and 21 pg/ml at
day 6 in patient 3 (3rd row of panels). IL-10 became detect-
able at low levels (i.e. <10 pg/ml) in all three patients (5th
row of panels); this cytokine peaked at day 9 in patient 1
and at day 19 in patient 2. In the latter patient, this pattern
coincided with only a minor IL-5 response during the sec-
ond treatment cycle.
Virtually no TNF- was detected prior to, during and
after therapy except for one observation in patient 1 (4th
row of panels). Finally, virtually no IL-4 responses were
seen in patients 1 and 2 (lower row of panels); patient 3
stood out by detectable IL-4 levels prior to therapy, which
remained at similar levels during and after treatment.
Discussion
We sought in vivo evidence for scFv(G250) receptor-medi-
ated T-cell functions as the infusion of scFv(G250)-retar-
geted T-cells clearly correlated in time with the induction
of liver toxicity. This toxicity is likely to be the result of the
speciWc immune reaction of the retargeted T-cells directed
against CAIX expressed by epithelial cells lining the bile
ducts [7]. Here, we show that PBMC taken from patients on
therapy—during which scFv(G250)+ T cells were detect-
able by Xow cytometry and PCR—displayed similar
scFv(G250) receptor-mediated functions as did
scFv(G250)+ T-cells prior to infusion, such as cytokine pro-
duction after exposure to CAIX and killing of CAIX+ RCC
cell lines.
We focused on Xuctuations in plasma cytokine levels as
markers for the in vivo activity of the scFv(G250)+ T cells.
ScFv(G250)+ T lymphocytes prior to infusion produced
high levels of IFN- and moderate levels of IL-5 upon
CAIX stimulation, whereas PBMC taken from patients dur-
ing therapy produced only moderate levels of IFN- and no
IL-5 upon ex vivo exposure to CAIX. On the contrary, we
observed signiWcant plasma levels of IFN- and IL-5 during
therapy. The Xuctuations in plasma IFN- levels varied
strongly between patients, with the highest increment in
patient 1 with the most pronounced liver toxicity. We have
Fig. 4 Kinetics of circulating scFv(G250)+ T-cell counts (upper pan-
els) and scFv(G250) DNA copy numbers (lower panels) in blood sam-
ples obtained before, during and following treatment with
scFv(G250)+ T cells in patient 1 and 2. Results of patient 3 have been
published elsewhere (see Ref. [14]). In the upper panels, closed circles
connected by uninterrupted lines indicate data points with proportions
of scFv(G250)+ cells above the detection limit of 6 in 10,000 CD3+ T
cells (see Ref. [14]). In the lower panels, the dashed lines indicate the
detection limit as deWned by the 95th percentile of ten blood samples
of healthy donors, i.e. 1 scFv(G250) DNA copy per l. The mean num-
ber of scFv(G250) DNA copies per scFv(G250)+ T cell in the T cell
infusions were 2.3 for patient 1, and 4.5 and 6.8 for treatment cycles 1
and 2, respectively, of patient 2. Horizontal bars indicate treatment
intervals, see further legend to Fig. 2123
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levels in patient 2; an as yet unidentiWed (auto) immune
activation, possibly combined with a ‘high IFN- genotype’
[16] given the elevated IFN- level prior to treatment, may
have contributed to this pattern. The plasma IFN- levels in
patient 2 normalized during the second course of treatment,
which was paralleled by relatively high CAIX-speciWc pro-
duction capacity of the inhibitory cytokine IL-10 and an
increment of plasma IL-10 levels in this patient.
To determine whether the increments in plasma IFN-
and IL-5 levels would reXect in vivo activity of the
scFv(G250)+ T cells or be related to the IL-2 administra-
tions only, we considered the following aspects.
Adoptive transfer of T cells has often been combined
with administration of exogenous rIL-2 in order to promote
survival of the transferred T cells, and to support and main-
tain T-cell activity in vivo [17–19]. Our observation that
the highest levels of scFv(G250)-mediated in vitro activity
of patient PBMC, in terms of both scFv(G250)-mediated
cytotoxicity and cytokine production, were detected during
the period of IL-2 administration, is in line with this
paradigm.
Only few studies have addressed the eVects of low-dose
IL-2-based treatment protocols on plasma cytokine levels.
Cragun et al [20] performed weekly assessments of serum
cytokine levels in patients receiving daily injections of
3 £ 106 IU/m2/day for 6 weeks and showed a gradual
increase of IL-5 from week 2 of treatment onwards, whilst
levels of IFN-, IL-4 en GM-CSF did not change. Gene
expression proWling of PBMC following 3 h of in vivo or
in vitro exposure to IL-2 identiWed 155 genes, including IL-
5 and IFN-, whose expression levels were increased
>threefold over those in non-exposed samples [21, 22]. In
addition, multiplex protein analysis of RCC patient serum
showed that IFN- and IL-5 levels increased signiWcantly
within 3 h following administration of a single high dose of
rhuIL-2 (0.72 £ 106 IU/kg). However, IFN- levels did not
increase further upon repeated IL-2 administrations, in con-
trast to those of other cytokines such as TNF-, IL-5 and
IL-10 [23]. The discrepancy between the short term (i.e.
within 4 h) [21, 22] and long term (i.e. 24 h) [20] eVects of
IL-2 administrations on IFN- and IL-5 plasma levels may
be related to the diVerent stabilities of IFN- and IL-5
mRNA in T-cells; their half-life is »2 and »4 h, respec-
Fig. 5 Kinetics of scFv(G250)-mediated cytotoxicity (upper row) and
CAIX-speciWc cytokine production [IFN- (2nd row) and IL-5 (3rd
row)] by PBMC obtained before and after therapy. PBMC were incu-
bated with CAIX+ RCC cells (open triangles), and CAIX+ RCC cells
in the presence of G250 blocking mAb (closed triangles). SpeciWc
cytolysis is expressed as LU20/106 PBMC and cytokine production in
pg/ml. The net scFv(G250)-mediated cytolysis (closed circles) is deW-
ned as the level of cytolysis of CAIX+ RCC cells minus the cytolysis
of CAIX+ RCC cells in the presence of G250 mAb. The net
scFv(G250)-mediated cytokine production (closed circles) is deWned
as the amount of cytokine produced in presence of CAIX+ RCC cells
minus the amount of IFN- produced in presence of CAIX+ RCC cells
and G250 mAb. See also the legends to Fig. 2123
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(i.e. once every 12 h), the relatively long half-life of IL-5
mRNA may explain the gradual increment of plasma IL-5
levels. The shorter half-life of IFN- mRNA would pre-
clude such an eVect on plasma IFN- levels.
On the basis of these combined studies, we propose that
the observed increments in plasma IL-5 levels are a ‘direct’
eVect of the IL-2 injections, and probably do not reXect
in vivo activity of the infused scFv(G250)+ T cells. On the
contrary, the observed increments in plasma IFN- levels
cannot completely be attributed to the IL-2 injections—due
to the short half-life of its mRNA—and therefore would
reXect in vivo activity of scFv(G250)+ T cells. This mecha-
nism would especially be apparent in patient 1, which
received the highest number of scFv(G250)+ T cells, and
developed the most severe liver toxicity.
Fig. 6 Kinetics of plasma cyto-
kine levels in blood samples of 
individual patients obtained be-
fore, during and following im-
muno-gene therapy. During the 
period of rIL-2 administration, 
blood samples were drawn just 
before s.c. rIL-2 injection, ex-
cepted for samples marked with 
asterisks (** = 2 h, and * = 4 h 
after rIL-2 administration); 
dashed line, detection limit. See 
further the legend to Fig. 2123
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